Phase II study of rituximab after priming with IFN in patients with relapsed LG/F B-cell lymphoma.

被引：0

作者：

Sacchi, S

Federico, M

Vitolo, U

Boccomini, C

Vallisa, G

Baldini, L

Petrini, M

Rupoli, S

Di Raimondo, F

Merli, F

Liso, V

Tabilio, A

Saglio, G

Di Renzo, N

Gobbi, P

Pitini, G

Quarta, G

Brugiatelli, M

Vinci, G

Dastoli, G

机构：

[1] Univ Modena, I-41100 Modena, Italy

[2] O Molinette, Div Emat, Turin, Italy

[3] Div Emat, Piacenza, Italy

[4] Univ Milan, Div Emat, Milan, Italy

[5] Univ Pisa, Div Emat, Pisa, Italy

[6] Univ Ancona, Div Emat, Ancona, Italy

[7] Catania Univ, Div Emat, Catania, Italy

[8] Div Emat, Reggio Emilia, Italy

[9] Univ Bari, Div Emat, Bari, Italy

[10] Univ Perugia, Div Emat, I-06100 Perugia, Italy

[11] Univ Turin, Div Emat, Turin, Italy

[12] S Giovanni Rotondo FG, Div Emat, San Giovanni Rotondo, Italy

[13] Univ Pavia, I-27100 Pavia, Italy

[14] Univ Messina, I-98100 Messina, Italy

[15] Div Emat, Reggio Calabria, Italy

[16] Roche SPA, Milan, Italy

来源：

BLOOD | 1999年 / 94卷 / 10期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

399

引用

页码：91A / 91A

页数：1